Abstract:An increase in SP‐A and SP‐D amount has been seen in the moderate COVID‐19, but in the severe stages of the disease due to the destruction of type 2 alveolar cells, which are the main producers of surfactants, these amounts will be reduced. Background Severe cases of COVID‐19 often lead to the development of acute respiratory syndrome, a critical condition believed to be caused by the harmful effects of SARS‐CoV‐2 on type II alveolar cells. These cells play a crucial role in producing pulmonary surfactants, which are essential for proper lung function. Specifically focusing on surfactant proteins, including Surfactant protein A (SP‐A), Surfactant protein B, Surfactant protein C, and Surfactant protein D (SP‐D), changes in the levels of pulmonary surfactants may be a significant factor in the pathological changes seen in COVID‐19 infection. Objective This study aims to gain insights into surfactants, particularly their impacts and changes during COVID‐19 infection, through a comprehensive review of current literature. The study focuses on the function of surfactants as prognostic markers, diagnostic factors, and essential components in the management and treatment of COVID‐19. Finding In general, pulmonary surfactants serve to reduce the surface tension at the gas–liquid interface, thereby significantly contributing to the regulation of respiratory mechanics. Additionally, these surfactants play a crucial role in the innate immune system within the pulmonary microenvironment. Within the spectrum of COVID‐19 infections, a compelling association is observed, characterized by elevated levels of SP‐D and SP‐A across a range of manifestations from mild to severe pneumonia. The sudden decline in respiratory function observed in COVID‐19 patients may be attributed to the decreased synthesis of surfactants by type II alveolar cells. Conclusion Collectin proteins such as SP‐A and SP‐D show promise as biomarkers, offering potential avenues for predicting and monitoring pulmonary alveolar injury in the context of COVID‐19. This clarification enhances our understanding of the molecular complexities contributing to respiratory complications in severe COVID‐19 cases, providing a foundation for targeted therapeutic approaches using surfactants and refined clinical management strategies.

Changes in the pulmonary surfactant in patients with mild COVID-19

Longitudinal Clinical and Radiographic Evaluation Reveals Interleukin-6 As an Indicator of Persistent Pulmonary Injury in COVID-19

Multicentric investigations of the role in the disease severity of accelerated phospholipid changes in COVID-19 patient airway

Unraveling the enigma: The emerging significance of pulmonary surfactant proteins in predicting, diagnosing, and managing COVID‐19

Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge

Impact of Coronavirus Disease 2019 on Pulmonary Function in Early Convalescence Phase

Biophysical parameters affecting lung surfactant function, surface tension and the transition from aerosol to droplet exhalation (in relation to COVID-19 infection)

Lipid Mediators and Cytokines/Chemokines Display Differential Profiles in Severe versus Mild/Moderate COVID-19 Patients

Proteomic blood profiling in mild, severe and critical COVID-19 patients

Molecular Pathogenesis of Fibrosis, Thrombosis and Surfactant Dysfunction in the Lungs of Severe COVID-19 Patients

Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19

High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients

Complex changes in serum protein levels in COVID-19 convalescents

The proteomic characteristics of airway mucus from critical ill COVID-19 patients

Mediators of monocyte chemotaxis and matrix remodeling are associated with mortality and pulmonary fibroproliferation in patients with severe COVID-19

The Serpin-tine Search for Factors Associated with COVID-19 Severity in Patients with Chronic Obstructive Pulmonary Disease

Lipidomic and Metabolomic Changes in Community-acquired and COVID-19 Pneumonia

Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID‐19 patients

Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients

Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components